Evaluating Reverse Payment Settlements After Actavis
On June 17, in a 5-3 decision, the U.S. Supreme Court ruled in Federal Trade Commission v. Actavis that reverse payment settlements between branded and generic pharmaceutical companies should be subject...To view the full article, register now.
Already a subscriber? Click here to view full article